GeoVax Announces Issuance of Hepatitis B Vaccine Patent
July 07, 2021 09:00 ET
|
GeoVax, Inc.
Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide ATLANTA, GA, July 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the...
首个抗肿瘤候选植物药“YIV-906”与索拉非尼联合治疗肝细胞癌的IIb期临床试验正式启动
April 06, 2020 07:00 ET
|
Yiviva
—— 利用整合系统生物学方法，由耶鲁大学郑永齐教授和医起共同开发的首个抗肿瘤候选植物药 中国上海，美国纽约, April 06, 2020 (GLOBE NEWSWIRE) -- 生物制药创新企业医起医药科技有限公司（Yiviva Inc.），在2020年初正式启动了YIV-906联合索拉非尼治疗乙型肝炎相关性肝细胞癌（HCC）的一线疗法IIb期研究，并于今年三月迎来了第一位受试者。 ...
Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy in the Treatment of Hepatocellular Carcinoma
April 06, 2020 07:00 ET
|
Yiviva
- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach -- Global study to evaluate efficacy, safety, and quality of life in patients with hepatitis...
Actor Ernie Hudson to serve as national spokesperson for Think About the Link
December 16, 2019 12:48 ET
|
Prevent Cancer Foundation
Alexandria, Va., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Ernie Hudson is best known for his role in the 1984 cult classic, Ghostbusters; however few fans know him as two-time cancer survivor. Hudson was...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 17, 2019 06:00 ET
|
VBI Vaccines, Inc.
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 01, 2019 08:00 ET
|
VBI Vaccines, Inc.
All four lead pipeline programs progressing towards expected clinical milestones in 2019Gearing up for top-line data from the pivotal Phase 3 study of Sci-B-Vac®, VBI’s trivalent hepatitis B vaccine,...
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
April 09, 2019 08:00 ET
|
VBI Vaccines, Inc.
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccineIn all three studies, seroprotection rates of more than 98%...
VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
March 18, 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
February 25, 2019 08:00 ET
|
VBI Vaccines, Inc.
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...